Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISLB 2021 | Liquid biopsy: monitoring recurrence in high-risk ovarian cancer

Sergio Marchini • 19 Oct 2021
ISLB 2021
Ovarian Cancer

Sergio Marchini, PhD, IRCCS, Humanitas Research Hospital, Milan, Italy, discusses using liquid biopsy early in the clinical setting to monitor recurrence in high-risk ovarian cancer. This interview took place at the International Society of Liquid Biopsy (ISLB) 2021 Virtual Meeting.

Disclosures

Roche Diagnostic, AstraZeneca MSD, Tesaro

More from Sergio Marchini

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:49
MITO-16a/MANGO-OV2a: plasma TF as a prognostic marker in ovarian cancer
Sergio Marchini • 8 Apr 2024
0:33
Will liquid biopsy replace traditional diagnostic methods?
Sergio Marchini • 19 Oct 2021

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
0:49
MITO-16a/MANGO-OV2a: plasma TF as a prognostic marker in ovarian cancer
Sergio Marchini • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals